166 related articles for article (PubMed ID: 24867282)
1. Computational approaches to the design of novel 5-HT6 R ligands.
Ivanenkov YA; Majouga AG; Veselov MS; Chufarova NV; Baranovsky SS; Filkov GI
Rev Neurosci; 2014; 25(3):451-67. PubMed ID: 24867282
[TBL] [Abstract][Full Text] [Related]
2. Serotonin receptor ligands and the treatment of obesity.
Vickers SP; Dourish CT
Curr Opin Investig Drugs; 2004 Apr; 5(4):377-88. PubMed ID: 15134278
[TBL] [Abstract][Full Text] [Related]
3. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.
Ivachtchenko AV; Ivanenkov YA; Skorenko AV
Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857
[TBL] [Abstract][Full Text] [Related]
4. Identification of a series of benzoxazoles as potent 5-HT6 ligands.
Liu KG; Lo JR; Comery TA; Zhang GM; Zhang JY; Kowal DM; Smith DL; Di L; Kerns EH; Schechter LE; Robichaud AJ
Bioorg Med Chem Lett; 2009 Feb; 19(4):1115-7. PubMed ID: 19152787
[TBL] [Abstract][Full Text] [Related]
5. 1-Sulfonylindazoles as potent and selective 5-HT6 ligands.
Liu KG; Lo JR; Comery TA; Zhang GM; Zhang JY; Kowal DM; Smith DL; Di L; Kerns EH; Schechter LE; Robichaud AJ
Bioorg Med Chem Lett; 2009 May; 19(9):2413-5. PubMed ID: 19345582
[TBL] [Abstract][Full Text] [Related]
6. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group.
Hayat F; Cho S; Rhim H; Indu Viswanath AN; Pae AN; Lee JY; Choo DJ; Choo HY
Bioorg Med Chem; 2013 Sep; 21(17):5573-82. PubMed ID: 23810425
[TBL] [Abstract][Full Text] [Related]
8. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives.
Ivachtchenko AV; Ivanenkov YA
Expert Opin Ther Pat; 2012 Aug; 22(8):917-64. PubMed ID: 22816965
[TBL] [Abstract][Full Text] [Related]
9. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia.
Nikiforuk A
Rev Neurosci; 2014; 25(3):367-82. PubMed ID: 24501158
[TBL] [Abstract][Full Text] [Related]
10. Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands.
Krogsgaard-Larsen N; Jensen AA; Schrøder TJ; Christoffersen CT; Kehler J
J Med Chem; 2014 Jul; 57(13):5823-8. PubMed ID: 24878269
[TBL] [Abstract][Full Text] [Related]
11. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
Geldenhuys WJ; Van der Schyf CJ
Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationship of novel conformationally restricted analogues of serotonin as 5-HT6 receptor ligands.
Nirogi RV; Kambhampati R; Kothmirkar P; Konda J; Bandyala TR; Gudla P; Arepalli S; Gangadasari NP; Shinde AK; Deshpande AD; Dwarampudi A; Chindhe AK; Dubey PK
J Enzyme Inhib Med Chem; 2012 Jun; 27(3):443-50. PubMed ID: 21774748
[TBL] [Abstract][Full Text] [Related]
13. Memory formation and memory alterations: 5-HT6 and 5-HT7 receptors, novel alternative.
Meneses A
Rev Neurosci; 2014; 25(3):325-56. PubMed ID: 24698823
[TBL] [Abstract][Full Text] [Related]
14. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia.
Johnson CN; Ahmed M; Miller ND
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):642-54. PubMed ID: 18729016
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways.
Romero G; Sánchez E; Pujol M; Pérez P; Codony X; Holenz J; Buschmann H; Pauwels PJ
Br J Pharmacol; 2006 Aug; 148(8):1133-43. PubMed ID: 16865095
[TBL] [Abstract][Full Text] [Related]
16. 6-Sulfonylbenzothiazolones as potential scaffolds for the design of 5-HT6 ligands.
Larchanche PE; Ultré V; Le Broc D; Ballandone C; Furman C; Dallemagne P; Melnyk P; Carato P
Eur J Med Chem; 2015 Mar; 92():807-17. PubMed ID: 25637882
[TBL] [Abstract][Full Text] [Related]
17. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
Holenz J; Pauwels PJ; Díaz JL; Mercè R; Codony X; Buschmann H
Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
[TBL] [Abstract][Full Text] [Related]
18. Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.
Leopoldo M; Lacivita E; Berardi F; Perrone R; Hedlund PB
Pharmacol Ther; 2011 Feb; 129(2):120-48. PubMed ID: 20923682
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 5-HT6 receptor ligands based on virtual HTS.
Tasler S; Kraus J; Wuzik A; Müller O; Aschenbrenner A; Cubero E; Pascual R; Quintana-Ruiz JR; Dordal A; Mercè R; Codony X
Bioorg Med Chem Lett; 2007 Nov; 17(22):6224-9. PubMed ID: 17892934
[TBL] [Abstract][Full Text] [Related]
20. Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor.
Parker CA; Gunn RN; Rabiner EA; Slifstein M; Comley R; Salinas C; Johnson CN; Jakobsen S; Houle S; Laruelle M; Cunningham VJ; Martarello L
J Nucl Med; 2012 Feb; 53(2):295-303. PubMed ID: 22223878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
